Fig. 5.

AKT inhibition impaired MSC-sEV-induced therapeutic effects in vitro. A Western blot analysis for the expressions of NRF2 and p-AKT in RPE cells treated with LY294002. B Immunofluorescence staining of NRF2 in RPE cells treated with LY294002. Scale bars, 25 μm. C Detection of ROS generation in RPE cells treated with LY294002. Scale bars, 100 μm. D CCK8 assay for the proliferation ability of RPE cells treated with LY294002 (n = 4). E Western blot analysis for the expressions of PCNA, Bcl-2 and Bax in RPE cells treated with LY294002. F Representative immunofluorescence staining images of Ki-67 in RPE cells treated with LY294002. Scale bars, 25 μm. All data are presented as means ± SEM. ns, not significant, *P < 0.05, **P < 0.01 and ***P < 0.001